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Abstract
Background: Recent animal and human studies implicate chronic activation of microglia in the
progressive loss of CNS neurons. The inflammatory mechanisms that have neurotoxic effects and
contribute to neurodegeneration need to be elucidated and specifically targeted without interfering
with the neuroprotective effects of glial activities. Synthetic triterpenoid analogs of oleanolic acid,
such as methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me, RTA 402) have potent
anti-proliferative and differentiating effects on tumor cells, and anti-inflammatory activities on
activated macrophages. We hypothesized that CDDO-Me may be able to suppress neurotoxic
microglial activities while enhancing those that promote neuronal survival. Therefore, the aims of
our study were to identify specific microglial activities modulated by CDDO-Me in vitro, and to
determine the extent to which this modulation affords neuroprotection against inflammatory
stimuli.
Methods: We tested the synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-
oate (CDDO-Me, RTA 402) in various in vitro assays using the murine BV2 microglia cell line, mouse
primary microglia, or mouse primary peritoneal macrophages to investigate its effects on
proliferation, inflammatory gene expression, cytokine secretion, and phagocytosis. The antioxidant
and neuroprotective effects of CDDO-Me were also investigated in primary neuron/glia cultures
from rat basal forebrain or ventral midbrain.
Results:  We found that at low nanomolar concentrations, treatment of rat primary
mesencephalon neuron/glia cultures with CDDO-Me resulted in attenuated LPS-, TNF- or fibrillar
amyloid beta 1–42 (Aβ1–42) peptide-induced increases in reactive microglia and inflammatory gene
expression without an overall effect on cell viability. In functional assays CDDO-Me blocked death
in the dopaminergic neuron-like cell line MN9D induced by conditioned media (CM) of LPS-
stimulated BV2 microglia, but did not block cell death induced by addition of TNF to MN9D cells,
suggesting that dopaminergic neuroprotection by CDDO-Me involved inhibition of microglial-
derived cytokine production and not direct inhibition of TNF-dependent pro-apoptotic pathways.
Multiplexed immunoassays of CM from LPS-stimulated microglia confirmed that CDDO-Me-
treated BV2 cells produced decreased levels of specific subsets of cytokines, in particular TNF.
Lastly, CDDO-Me enhanced phagocytic activity of BV2 cells in a stimulus-specific manner but
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inhibited generation of reactive oxygen species (ROS) in mixed neuron/glia basal forebrain cultures
and dopaminergic cells.
Conclusion: The neuroimmune modulatory properties of CDDO-Me indicate that this potent
antioxidant and anti-inflammatory compound may have therapeutic potential to modify the course
of neurodegenerative diseases characterized by chronic neuroinflammation and amyloid
deposition. The extent to which synthetic triterpenoids afford therapeutic benefit in animal models
of Parkinson's and Alzheimer's disease deserves further investigation.
Background
Plant-derived triterpenoids, including oleanolic acid and
ursolic acid, have been used extensively in Asian countries
for their anti-inflammatory and anti-tumor properties [1].
In an attempt to increase the potency of these natural
products, over 300 synthetic derivatives of oleanolic acid
were generated and tested for their ability to inhibit NO
production in activated macrophages [2-4]. Some of the
most potent of these, including 2-cyano-3,12-
dioxooleana-1,9-dien-28-oic acid (CDDO; RTA 401) and
its methyl ester (CDDO-Me; RTA 402), exhibit greater
than 2 × 105-fold increased potency compared to the
parental compound. CDDO-Me is presently in Phase I/II
clinical trials for the treatment of solid tumors. In light of
their potent bioactivity, this new class of compounds has
therapeutic potential in the treatment and prevention of
acute and chronic inflammatory syndromes.
Although identification of the molecular targets of triter-
penoids is just underway, a number of recent studies have
identified key mechanisms that mediate the potent effects
of triterpenoids. One of these mechanisms involves
decreasing the levels of reactive oxygen species (ROS)
through activation of Nrf2-dependent transcription [5,6].
In addition, the triterpenoids directly inhibit NF-κB sign-
aling [7,8], a key pathway that regulates the production of
a number of inflammatory mediators and their signaling
cascades (e.g. TNF, IL-1β, IFNγ, TLR) [9]. Increased levels
of antioxidant enzymes produced by Nrf2 reduce the cel-
lular levels of ROS, thereby further attenuating NF-κB sig-
naling and the transcription of pro-inflammatory genes
such as iNOS and TNF [5,10,11].
The role of neuroinflammation in neurodegenerative dis-
ease has been under intense investigation in recent years
and there is now overwhelming evidence that inflamma-
tion-induced oxidative stress compromises neuronal sur-
vival and may contribute to the progression of
neurodegenerative diseases including Parkinson's (PD)
and Alzheimer's disease (AD) (reviewed in [12-18]). We
reasoned that if CDDO-Me were able to suppress micro-
glial activities that contribute to neurotoxicity while pro-
moting those that support neuronal survival, it may be
capable of exerting neuroprotective effects. Therefore, the
overall purpose of these studies was to investigate the cel-
lular basis for the anti-inflammatory properties of CDDO-
Me; specifically, to identify microglial activities modu-
lated by CDDO-Me in vitro and the extent to which this
modulation protects against inflammatory stimuli.
Methods
Animals
Experimental procedures involving use of animal tissue
were performed in accordance with the NIH Guidelines
for Animal Care and Use and approved by the Institu-
tional Animal Care and Use Committee (IACUC) at The
University of Texas Southwestern Medical Center in Dal-
las. Animals were housed in a climate controlled facility
staffed with certified veterinarians.
CDDO-Me
Lyophilized stocks of the synthetic triterpenoid CDDO-
Me (RTA 402) were stored at -20°C until they were dis-
solved in DMSO.
Cell culture
The murine BV2 microglia cell line was generated by Dr.
Bistoni and colleagues by infecting primary microglial cell
cultures with the v-raf/v-myc oncogene carrying retrovirus
J2. These cells retain many of the morphological, pheno-
typical and functional properties described for freshly iso-
lated microglial cells [19]. BV2 microglia were cultured in
DMEM/F12 supplemented with 5% heat-inactivated fetal
bovine serum (Sigma-Aldrich, St Louis MO), 1% penicil-
lin-streptomycin, and 1% L-glutamine. The murine clonal
hybrid cell line MN9D was developed by A. Heller and
colleagues by somatic cell fusion of rostral mesencephalic
tegmentum (RMT) from 14-day-old embryonic mice and
the murine neuroblastoma cell line N18TG2 [20]. MN9D
cells were grown in DMEM (Sigma-Aldrich) supple-
mented with 10% FBS (Gemini, West Sacramento CA),
and 1% penicillin/streptomycin. To induce terminal dif-
ferentiation of MN9D cells and increase their sensitivity to
apoptotic stimuli, cells were incubated with 5 mM of val-
proic acid in N2 (Invitrogen, Carlsbad, CA)-supple-
mented serum-free DMEM for 3 days. Primary microglia
were harvested from postnatal day 2–4 mouse pups using
previously published protocols [21]. Briefly, brain tissue
was removed, finely minced with a razor, incubated in a
dissociation media containing 1 μL/mL DNAseI (Invitro-Journal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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gen), 1.2 U/mL dispase II (Roche), and 1 mg/mL papain
(Sigma-Aldrich) in DMEM/F12 (Sigma-Aldrich) for 30–
45 minutes at 37°C. After mechanical trituration, cells
were centrifuged, passed through a 40 μM filter (BD Fal-
con, San Jose CA), and plated at 500,000 total cells/well
in 6 well plates pre-coated with 0.1 mg/mL poly-D lysine
(Sigma). Cells were fed every 3 days with fresh media
(DMEM/F12 supplemented with 10% heat-inactivated
fetal bovine serum (Sigma-Aldrich), 1% penicillin-strep-
tomycin, and 1% L-glutamine). After 14–18 days in vitro,
cultures were treated with 0.0625% trypsin-EDTA (diluted
in DMEM/F12) for 45 minutes at 37°C to lift astrocytes
and neurons from the wells, leaving a pure culture of pri-
mary microglia. The cultures were checked for purity and
found to be greater than 95% microglia as measured by
cell-type specific expression of CD68 and less than 5%
astrocytes as measured by GFAP immunoreactivity.
Murine peritoneal macrophages were obtained by elicit-
ing an acute peripheral inflammatory reaction with intra-
peritoneal injection of thioglycolate [22]. Briefly, adult
mice were injected intraperitoneally with 1 mL 3%
Brewer's yeast thioglycolate. Three days later the animals
were sacrificed, and 10 mL of cold sterile PBS (pH 7.4)
was injected into the peritoneal cavity to wash out and
recover peritoneal exudate. Cells were pelleted (1000
rpm, 5 min, 4°C), resuspended in culture media (high
glucose DMEM supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA), and 1%
penicillin, streptomycin, and L-glutamine) and allowed to
adhere to culture plates for 6 hr. Cells were washed twice
with PBS to remove non-adherent cells and growth
medium was replenished.
Aggregation of amyloid beta peptide
Aβ 1–42 peptide was synthesized by Dr. Haydn Ball in the
Protein Chemistry Core at UT Southwestern. Aggregation
into fibrillar form was achieved by resuspending the pep-
tide at final concentration of 100 μM into phosphate-buff-
ered saline and incubating it at 37°C for 48 hrs.
Thioflavin T fluorescence [23] and Congo Red binding in
vitro was used to confirm fibril formation [24].
Microglia proliferation and viability assays
Cell viability and proliferation were assayed in the BV2
microglia cell line using the Alamar Blue reagent (Invitro-
gen). Cells were seeded at 2000 cells/well in a 96-well
plate. Cells were serum deprived for 3–5 hours, and
CDDO-Me was added 1 hour before treatment with LPS as
indicated. Alamar Blue was added as per the manufacturer
instructions 2 hr before absorbance was read at 570 nm
and 595 nm.
Microglia activation assays
Rat embryonic ventral mesencephalon primary cultures
were harvested from E14 pups, mechanically dissociated
and seeded as micro-islands (25 uL of 1 × 106 cells/mL) on
4-chamber slides precoated with poly-D-lysine and lam-
inin (BD Bioscience) in DMEM/F12 with 1% penicillin/
streptomycin, glutamine, and non-essential amino acid
and containing 10% fetal bovine serum (Atlanta Biologi-
cals) and 10 ng/mL FGF-2 (R&D Systems, Minneapolis,
MN). Culture media was changed after 2 days in vitro and
cells were treated at day 5 in vitro with indicated com-
pounds in DMEM containing 2.5% FBS and lacking FGF-
2. Cells were fixed at 2 days post-treatment in 4% parafor-
maldehyde in PBS (pH 7.4) and stained with an antibody
against activation marker F4/80 (1:60 dilution Serotec,
Raleigh, NC) to quantify number of activated microglia.
Each condition was done in triplicate; 20 random sites
were visited per well; data was plotted as the average
number of F4/80-positive microglia per field.
Oligonucleotide microarrays
BV2 cells were plated at 500,000 cells/well in a 6-well
plate in DMEM with 5% FBS and switched to serum-free
media before pre-treatment with CDDO-Me or DMSO
vehicle and subsequent stimulation with LPS as indicated.
RNA was harvested as detailed below and levels of inflam-
mation-related gene expression were detected on an oligo-
nucleotide array as per manufacturer's instructions
(Superarray Bioscience Corporation, Frederick, MD). Data
analyses were performed using the Scatter Plot data anal-
ysis tool in the SuperArray GEArray Analysis Suite. The
Scatter Plot displays the fold difference in the relative
expression levels of genes between groups. Seven house-
keeping genes were used for normalization. The control
group was assigned to the X-Axis, and the treated group
was assigned to the Y-Axis. An arbitrary boundary of 1.5-
fold regulation in either direction was selected. If the fold
increase was greater than boundary value, the gene names
are shown in red with a plus (+) sign, and are located
above the upper line. The further the sign is from the
upper line, the greater the fold difference. If the fold
decrease is greater than the boundary value, the genes are
shown in green with a minus (-) sign, and are located
below the lower line. The further the sign is from the
lower line, the greater the fold difference. Black signs
mean the fold change is not significant.
Real time quantitative polymerase chain reaction
Real-time quantitative PCR (QPCR) was performed as
previously described [25]. Briefly, total RNA was isolated
from cultured cells or animal tissues using RNA Stat-60
(Tel-Test, Inc., Friendswood, TX), treated with DNase I
(Invitrogen), and reverse transcribed using Superscript II
RNase H-reverse transcriptase (Invitrogen). RNA concen-
tration was determined by absorbance at 260 nm. Quan-
titative real-time PCR was performed using an ABI Prism
7900 HT Fast Detection System (Applied Biosystems Inc.,
Foster City, CA). Each 10 μl reaction was performed inJournal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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384-well format with 25 ng cDNA, 5 μl SYBR green PCR
Master Mix, and 150 nM of each PCR primer. All reactions
were performed in duplicate. Levels of mRNA expression
were normalized to those of the mouse house-keeping
gene cyclophilin B. Oligonucleotide primers for QPCR
were obtained from Integrated DNA Technologies (Cor-
alville, IA). The following mouse primers sequences were
validated and used for gene amplification:
mTNF: forward 5'-CTG AGG TCA ATC TGC CCA AGT AC-
3' and reverse 5'-CTT CAC AGA GCA ATG ACT CCA AAG-
3'
mIL1β: forward 5'-CAA CCA ACA AGT GAT ATT CTC CAT
G-3' and reverse 5'-GAT CCA CAC TCT CCA GCT GCA-3'
mMip1α: forward 5'-TTC ATC GTT GAC TAT TTT GAA
ACC A-3' and reverse 5'-GCC GGT TTC TCT TAG TCA
GGA A-3
iNOS: forward 5'-CAG GAG GAG AGA GAT CCG ATT TA-
3' and reverse 5'-GCA TTA GCA TGG AAG CAA AGA-3'
Multiplexed immunoassays
BV2 cells were plated at 500,000 cells/well in a 6-well
plate in DMEM containing 5% FBS and switched to
serum-free media before pre-treatment with CDDO-Me or
DMSO vehicle and subsequent stimulation of LPS as indi-
cated. Conditioned Medium (CM) was collected to meas-
ure the production of seven cytokines (IFN-γ, IL-1β, IL-6,
IL-10, IL-12, KC/CXCL1, and TNF) using a multiplexed
immunoassay per the manufacturer instructions (Meso-
Scale Discovery, Gaithersburg, MD).
Intracellular reactive oxygen species (ROS) imaging
Rat embryonic ventral mesencephalon neuron/glia cul-
tures were prepared as published previously [26]. At 5
days  in vitro (5 DIV), they were incubated with 3 μM
DCFDA (Invitrogen) in serum-free growth medium for 40
min to quantify intracellular reactive oxygen species
(ROS) production by fluorescence imaging. The next day,
cells were treated with the vehicle, 1 μM fibrillar amyloid
beta (Aβ) 42 peptide plus or minus 10 ng/mL LPS in the
presence or absence of CDDO-Me as indicated for 24 hrs.
Fluorescence images were captured on an Olympus CK40
microscope with a CoolSnap CCD ES monochromatic
camera with a FITC filter in place. Quantification of fluo-
rescence intensity was performed using intensity thresh-
old analysis of digital images on an Alpha Innotech
ChemiImager 4400 (Alpha Innotech, San Leandro, CA).
MN9D dopaminergic cells were plated at 50,000 cells per
well in DMEM containing 10% FBS in 24 well plates. The
following day cultures were differentiated in N2 supple-
mented serum-free DMEM containing 5 mM valproic
acid. 48 hours following differentiation MN9D cells were
incubated with 3 uM DCFDA in serum free DMEM for 40
min, and then returned to differentiation media. Six hours
after DCFDA loading, MN9D cells were treated with 10
nM CDDO-Me (or DMSO vehicle) for 16–20 hrs before a
30 minute stimulation with either TNF or conditioned
media from LPS and CDDO-Me treated BV2 microglial
cultures. BV2 microglial cultures for these experiments
were plated in DMEM containing 5% FBS at 800,000 cells
per well in a 6-well plate. Cultures were permitted to
adhere to the plastic and then were pretreated with 10 nM
CDDO-Me (or DMSO vehicle) for 16–18 hrs prior to
stimulation with 10 ng/mL LPS (or saline vehicle). The
following day conditioned media from BV2 cultures was
removed and centrifuged at 1200 × g for 4 min before
addition to DCFDA-loaded, differentiated MN9D
dopaminergic cultures. Fluorescence images were cap-
tured on an Olympus CK40 microscope with a CoolSnap
CCD ES monochromatic camera with a FITC filter in
place. Quantification of ROS accumulation was per-
formed by counting DCFDA-positive cell bodies in four
fields per condition under 20× magnification (equivalent
to approximately 50% of the plated area per well) in two
independent experiments. DCFDA positive cells ranged
between 38 and 420 per field depending on experiment
and treatment. Values for treatment conditions in each
experiment were expressed as fold increase in DCFDA
positive cells per field relative to DMSO vehicle, saline
treated control, and averaged between independent exper-
iments.
Cell survival/neuroprotection assays
MN9D dopaminergic cells (grown as described above),
were terminally differentiated with 5 mM valproic acid in
N2-supplemented serum-free DMEM 3 days prior to neu-
roprotection studies with CDDO-Me. MN9D cell viability
was measured using the CellTiter 96 AQueous Assay reagent
(Promega, Madison, WI). This reagent uses the tetrazo-
lium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS) and the electron coupling reagent, phen-
azine methosulfate (PMS). MTS is chemically reduced
into soluble formazan in metabolically active cells.
MN9D cell viability was assayed by measurement of for-
mazan absorbance at 492 nm in multi-titer 96-well plates
at 492 nm during the last 2–4 hrs of a three-day incuba-
tion with soluble TNF or a two-day incubation with BV2
conditioned media in target-effector assays in which the
BV2 microglia cell line was used as the effector cell and the
MN9D dopaminergic ells as the target cell. Specifically,
conditioned medium (CM) from LPS-treated BV2 micro-
glia was transferred to MN9D cell cultures to induce
inflammation-induced death in a dose-dependent man-
ner.Journal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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Phagocytosis assays
BV2 microglia were plated at a density of 50,000 cells/well
in a 96-well plate and switched to serum-free media 24 hr
later for stimulation as indicated with LPS (10 ng/mL)
and/or fAβ (1 μM), in the presence or absence of CDDO-
Me (10 nM). After 24 hr stimulation, phagocytosis was
measured by exposing the cultures to fluorescently-
labeled E. coli particles (Invitrogen) for 2 hr. Cells were
incubated with trypan blue and rinsed with PBS to remove
non-internalized particles prior to measuring fluorescence
at 480 nm excitation and 520 nm emission on a Fluor-
oskan multiwell plate reader.
Results
CDDO-Me inhibits proliferation and activation of 
microglia
Neuroinflammatory processes are associated with a
number of neurodegenerative conditions and have been
implicated in the underlying progressive loss of neurons
[15,16,27-30]. Therefore, inflammatory factors and mech-
anisms that contribute to neurotoxicity and compromise
neuronal survival need to be elucidated and specifically
targeted without interfering with the neuroprotective
effects of glial activities [18]. Synthetic triterpenoids have
potent anti-proliferative and differentiating effects on
tumor cells and anti-inflammatory activities on activated
macrophages. Therefore, we hypothesized that CDDO-Me
may be able to promote neuronal survival by suppressing
neurotoxic microglial activities without compromising
overall microglial cell viability. In pilot experiments, we
established the concentration range of CDDO-Me beyond
which anti-proliferative and toxic effects could be detected
in a murine BV2 microglial cell line. We found that
CDDO-Me concentrations at or above 100 nM inhibited
the proliferative response to bacterial lipopolysaccharide
(LPS) as measured by Alamar blue reduction and that con-
centrations greater than 500 nM were toxic (data not
shown). Based on these results, we chose to use concentra-
tions of CDDO-Me at or below 100 nM for our studies.
We first investigated the ability of CDDO-Me to inhibit
activation of microglia in response to specific inflamma-
tory stimuli. Treatment of rat primary mesencephalon
neuron/glia cultures with CDDO-Me alone did not elicit
microglia activation; but CDDO-Me pre-treatment
resulted in attenuated LPS-, TNF- or fibrillar Aβ-induced
increase in microglial activation, as measured by the
number of F4/80-immunoreactive microglia (Fig. 1).
These findings suggested that differential modulation of
microglial activities might be possible at concentrations of
CDDO-Me below 100 nM without cytotoxic effects to the
cells.
CDDO-Me suppresses transcription of inflammatory 
mediators in microglia and macrophages
A number of microglial-derived mediators have been
reported to mediate neuronal death in experimental mod-
els of neurodegeneration (reviewed in [16]), raising the
possibility that anti-inflammatory therapies may be an
CDDO-Me attenuates LPS-, TNF-, and fibrillar Aβ42-induced  primary microglia activation Figure 1
CDDO-Me attenuates LPS-, TNF-, and fibrillar Aβ42-
induced primary microglia activation. Rat embryonic 
ventral mesencephalon primary cultures were treated at day 
5 in vitro with indicated compounds (LPS 10 ng/mL, TNF 5 ng/
mL, fAβ 1 μM, CDDO-Me 10 nM). Cells were fixed at 2 days 
post-treatment and stained with an antibody against the 
microglial activation marker F4/80. Values are expressed as 
mean number of F4/80-positive microglia per field ± S.E.M.. 
Values were analyzed by two-way ANOVA followed by 
Tukey post hoc test, * denotes CDDO-Me is significantly dif-
ferent from its DMSO vehicle for a given treatment; # 
denotes significant difference from the DMSO vehicle in 
unstimulated cells; + denotes significant difference from 
CDDO-Me in stimulated cells; all symbols at p < 0.05.
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effective means of delaying or attenuating neuron death.
Therefore, we investigated the ability of CDDO-Me to reg-
ulate expression of inflammation- and oxidative stress-
related genes in primary microglia, macrophages, and the
BV2 microglia cell line. We performed real-time quantita-
tive polymerase chain reaction (QPCR) to measure mRNA
levels for a number of inflammation-related genes. LPS-
induced production of TNF mRNA was significantly
reduced in all cell types while IL-1β mRNA was signifi-
cantly reduced in primary microglia and macrophages but
not BV2 cells (Fig. 2). CDDO-Me also significantly atten-
uated the LPS-induced mRNA expression of MIP-1α and
iNOS. Multiplexed immunoassay analysis of BV2 micro-
glia-conditioned medium (CM) confirmed that CDDO-
Me attenuated LPS-induced production of factors such as
IL-12, IL-6, and TNF all of which are known to promote
autocrine signaling in microglia (Fig. 3). Given that both
IL-6 and TNF can compromise DA neuron survival, these
findings raised the possibility that CDDO-Me may be able
to protect neuronal populations that display increased
vulnerability to inflammation-induced oxidative stress
and apoptotic death, in particular dopaminergic neurons
[16,31], by limiting the production of these neurotoxic
factors by chronically activated microglia without com-
promising other microglial functions. It should be noted,
however, that not all chemokines and cytokines typically
associated with pro-inflammatory responses were
depressed by exposure to CDDO-Me. For instance,
CDDO-Me increased production of CXCL1 (also known
as keratinocyte-derived chemokine (KC)), a potent chem-
oattractant to neutrophils [32] (Fig. 3). Curiously, while
CDDO-Me reduced (not significantly) LPS-induced IL-1β
mRNA in the BV2 microglia cell line (Fig. 2), it potenti-
ated secretion of this cytokine by BV2 cells (Fig. 3). The
reason for this effect is unclear but these findings raise the
interesting possibility that synthetic triterpenoids may be
able to differentially regulate inflammatory responses by
altering transcription of specific subsets of genes and per-
haps by modulation of post-transcriptional signaling cas-
cades that influence secretion of specific inflammatory
factors. Future research into this area will provide much
needed insight into other mechanisms of action for syn-
thetic triterpenoids.
To complement these findings and survey a larger number
of inflammation-related genes, we performed oligonucle-
otide gene arrays in BV2 microglia treated with saline or
LPS in the presence of CDDO-Me or its vehicle (DMSO).
In resting microglia, CDDO-Me upregulated the receptor
for a classic anti-inflammatory cytokine IL-10 while inhib-
iting basal expression of 12 inflammation-related genes,
including TNF, iNOS2, IL-18, MCP1 (CCL2), Mip1α
(CCL3), and Mip1β (CCL4) (Fig. 4a). These results indi-
cate CDDO-Me coordinately attenuates gene expression
of pro-inflammatory genes and enhances genes known to
be part of anti-inflammatory responses. As expected, stim-
ulation of BV2s with LPS triggered upregulation of the
gene for the pro-inflammatory cytokine TNF as well as
genes for the chemokines Mip1β (CCL4) and Mip1γ
(CCL9) while downregulating IL-15, IL-18, IL-2, and IL-8
(Fig. 4b). Consistent with the well-known fact that the
normal cellular response to an inflammatory stimulus is
to activate anti-inflammatory response loops to return the
cell to a pre-activation status, we also detected increased
IL-10 receptor expression in response to LPS. In support of
its anti-inflammatory properties, CDDO-Me attenuated
LPS-induced increases in pro-inflammatory gene expres-
sion including TNF and MCP1 (CCL2) (Fig. 4c); these
results are similar to those reported for CDDO-Im in LPS-
stimulated peripheral neutrophils [6]. In agreement with
real-time QPCR results, treatment with CDDO-Me
blocked the LPS-induced increases in iNOS, MIP1α, and
CCL2. Moreover, CDDO-Me was able to reverse the LPS-
induced downregulation of IL-15 and IL-2 genes (Fig. 4c).
Lastly, the oligonucleotide arrays indicated that expres-
sion of receptors for the anti-inflammatory cytokines IL-
10 and IL-13 as well as complement component (required
for destroying bacterial pathogens) were also upregulated
by CDDO-Me exposure (Fig. 4b, c), suggesting CDDO-Me
may be an effective anti-infective.
CDDO-Me attenuates microglial-mediated neuronal 
oxidative stress
Oxidative stress, which is defined as the cellular condition
when production of reactive oxygen and nitrogen species
(ROS/RNS) exceeds the capacity of antioxidant defenses,
is a trigger for glial activation and is a feature of most neu-
rological and neurodegenerative conditions. Therefore,
the use of antioxidants has been intensely investigated in
models of neurodegeneration for their direct neuroprotec-
tive effects and for their ability to protect by suppressing
the glial-mediated inflammatory response [33,34]. We
investigated the ability of CDDO-Me to inhibit intracellu-
lar accumulation of ROS using the cell permeant dye
DCFDA in mixed neuron-glia cultures from rat basal fore-
brain. Inflammation-induced intracellular ROS accumu-
lation was evident primarily in cells with morphological
characteristics consistent with that of neurons and to a
lesser extent in the surrounding glial cells after treatment
with LPS + fibrillar Aβ42 (Fig. 5a, b). Co-addition of
CDDO-Me to these cultures inhibited the intracellular
ROS accumulation induced by LPS + fibrillar Aβ42. The
accumulation of ROS in neuronal cells was confirmed by
treatment of the dopaminergic cell line MN9D with con-
ditioned media from LPS and CDDO-Me treated BV2
microglial cells. Pretreatment of BV2s with 10 nM CDDO-
Me before LPS exposure attenuated the ability of the con-
ditioned media (CM) from BV2 microglia cultures to
induce ROS accumulation in terminally differentiated
MN9D cultures (Fig. 5c). Pretreatment of differentiated Journal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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CDDO-Me downregulates expression of mRNAs for pro-inflammatory genes Figure 2
CDDO-Me downregulates expression of mRNAs for pro-inflammatory genes. (A) BV2 microglia were pre-treated 
with 10 nM CDDO-Me for 17 hr before a 4-hr stimulation as indicated. (B) Microglia from post-natal day 2 (P2) wild-type mice 
were pre-treated with 100 nM CDDO-Me for 24 hr before a 4 hr stimulation as indicated. (C) Peripheral macrophages from 
adult wild-type mice were pre-treated with 100 nM CDDO-Me for 24 hr before a 4-hr stimulation as indicated. Values repre-
sent mean ± S.E.M. and are expressed relative to vehicle-treated, vehicle-stimulated conditions. Values were analyzed by two-
way ANOVA followed by Bonferroni's post hoc. * denotes significance at p < 0.05, *** denotes significance at p < 0.001.
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CDDO-Me suppresses production of cytokines with known neurotoxic effects on dopaminergic cultures Figure 3
CDDO-Me suppresses production of cytokines with known neurotoxic effects on dopaminergic cultures. BV2 
microglia were pre-treated with 100 nM CDDO-Me or DMSO vehicle for 17 hrs before a 4-hr stimulation with LPS (10 ng/
mL). Inflammatory cytokine and chemokine production were measured from CM using a 7-plex inflammatory cytokine profile 
immunoassay from Meso-Scale Discovery on an MSD 2400 plate reader. Values represent mean cytokine production ± SEM. 
Values were analyzed by two way ANOVA followed by Bonferroni's post hoc. ** denotes significance at p < 0.01, *** denotes 
significance at p < 0.001.
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CDDO-Me suppresses basal and inflammation-induced gene expression Figure 4
CDDO-Me suppresses basal and inflammation-induced gene expression. BV2 microglia cultures were pre-incubated 
with 100 nM CDDO-Me for 17 hrs before a 4-hr stimulation with 10 ng/mL LPS in serum-free medium. (A) Scatterplot of base-
line inflammatory gene expression in unstimulated BV2 cells in the presence of DMSO vehicle (0.1%) versus unstimulated cells 
in the presence of 100 nM CDDO-Me. (B) Unstimulated cells in the presence of DMSO vehicle versus cells stimulated with LPS 
(10 ng/mL) in the presence of DMSO vehicle, or (C) cells stimulated with LPS in presence of DMSO vehicle versus cells stimu-
lated with LPS in the presence of 10 nM CDDO-Me plus. Data analyses were performed using the Scatter Plot data analysis 
tool in the SuperArray GEArray Analysis Suite online (See Methods). Genes shown with a red plus (+) sign were up-regulated 
and genes shown with a green minus (-) sign were down-regulated in the treatment condition, which is plotted on the Y-axis 
relative to the control condition plotted on the X-axis.
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CDDO-Me inhibits intracellular ROS accumulation induced by LPS and fibrillar Aβ42 in neuronal cultures from E14 rat basal  forebrain cholinergic mixed neuron-glia cultures (BFCs) and in dopaminergic cells Figure 5
CDDO-Me inhibits intracellular ROS accumulation induced by LPS and fibrillar Aβ42 in neuronal cultures 
from E14 rat basal forebrain cholinergic mixed neuron-glia cultures (BFCs) and in dopaminergic cells. (A) Fold-
change in intracellular ROS. Integrated optical density was measured from digital images of treated BFCs. Results are expressed 
as the mean ± S.E.M. of each condition relative to vehicle treatment. Values were analyzed by one-tailed Student's t-test, * 
denotes significance at p < 0.005. (B) BFCs loaded with the fluorescent indicator DCFDA. Intracellular ROS accumulation is 
evident after 24-hour treatment with 10 ng/mL LPS + 1 μM fAβ-42, but co-treatment with 100 nM CDDO-Me attenuated neu-
ronal ROS accumulation. Scale bar = 50 μm. (C) Target-effector ROS accumulation assays of MN9D dopaminergic cells 30 
minutes after transfer of conditioned medium (CM) from saline- or LPS-treated (24 hrs) BV2 microglia pre-incubated with 
CDDO-Me (10 nM) or vehicle (DMSO). (D) Direct treatment of MN9D dopaminergic cells with TNF (5 ng/mL) for 30 minutes 
after pre-incubation with CDDO-Me (10 nM) or vehicle (DMSO). (C, D) Values shown represent group means ± S.E.M of fold 
increase in DCFDA positive cell bodies relative to DMSO vehicle, saline treated control conditions and are averages of two 
independent experiments. Values were analyzed by two way ANOVA followed by Tukey's post hoc test. Groups denoted by 
different letters are significantly different at p < 0.05.Journal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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MN9Ds with CDDO-Me did not attenuate intracellular
ROS accumulation resulting from direct TNF treatment
(Fig 5d). Taken together, these findings suggest that the
mechanism by which CDDO-Me protects neuronal cells
may be primarily through changes in microglial-derived
mediators and not through direct anti-oxidant effects on
neuronal cells.
CDDO-Me protects the dopaminergic MN9D cell line 
from inflammation-induced death
Pro-inflammatory cytokines, in particular TNF, exert
potent toxic effects on dopaminergic neurons and have
been implicated in neurodegenerative disease pathogene-
sis [15,16,35,36]. To investigate the ability of CDDO-Me
to protect dopaminergic neuron-like cells from inflamma-
tion-induced death, we performed in vitro target-effector
cell survival assays. Survival of differentiated MN9D
dopaminergic cells was measured after direct incubation
with soluble TNF or in undifferentiated cultures after
incubation with CM from LPS-treated BV2 microglia cells.
We found that 10 nM CDDO-Me abolished MN9D cell
death induced by exposure to CM from LPS-stimulated
BV2 microglia (Fig. 6a), but ineffectively attenuated cell
death induced by the direct addition of TNF to MN9D
cells (Fig. 6b). These findings were consistent with a
mechanism by which the neuroprotective effects of
CDDO-Me in these assays are mediated by its ability to
inhibit microglial-derived TNF production (Fig. 3) or by
interfering with the intracellular site of action of other
neurotoxic cytokines elicited by LPS rather than by direct
inhibition of TNF-dependent death signaling by CDDO-
Me. To test this idea directly, we added the TNF decoy
receptor etanercept to bind and deplete soluble TNF from
CM of BV2 microglia stimulated with LPS alone or in
combination with CDDO-Me prior to CM transfer to
MN9D dopaminergic cells. In support of this model, we
found that etanercept attenuated MN9D cell death equiv-
alent to that obtained with CDDO-Me treatment alone
and together the two were not additive (Fig. 6a).
CDDO-Me enhancement of microglial phagocytic activity 
is stimulus-specific
Our findings that CDDO-Me attenuates production of
some but not all inflammatory mediators raised the inter-
esting possibility that other microglial activities could be
modulated differentially by CDDO-Me. To investigate the
ability of CDDO-Me to regulate phagocytic responses of
BV2 microglia, we stimulated the cells with different
inflammatory agents and analyzed their ability to phago-
cytose fluorescently labeled E. coli particles. We found that
CDDO-Me had minimal effect on basal phagocytic activ-
ity of BV2 microglia or phagocytosis induced by LPS, but
was able to enhance phagocytosis induced by TNF or
fibrillar Aβ1–42 peptide (Fig. 7). These findings suggest
stimulus-specific modulation of microglial phagocytosis
by CDDO-Me and warrant further investigation in models
of amyloid deposition.
CDDO-Me rescues dopaminergic MN9D cells by attenuating  LPS-induced TNF production rather than by direct inhibition  of TNF-induced death Figure 6
CDDO-Me rescues dopaminergic MN9D cells by 
attenuating LPS-induced TNF production rather 
than by direct inhibition of TNF-induced death. (A) 
MN9D cells were incubated with conditioned medium (CM) 
from BV2 microglia cultures stimulated with 0, 10 or 100 ng/
mL LPS alone or with the same concentrations of LPS plus 10 
nM CDDO-Me; 200 ng/mL etanercept; or both CDDO-Me 
and etanercept. Survival of MN9D cells was evaluated after 2 
days of incubation in the CM using an MTS viability assay (See 
Materials and Methods). (B) Differentiated MN9D dopamin-
ergic cells were treated with 0, 1, 3, or 5 ng/mL TNF alone 
or with the same concentrations of TNF plus 10 nM or 100 
nM CDDO-Me. Survival was evaluated after 3 days using an 
MTS viability assay. Results are expressed as mean ± SEM. 
Values were analyzed by one-way ANOVA followed by 
Tukey's post hoc, groups denoted by different letters are sig-
nificantly different from each other at p < 0.05.
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Discussion
Chronic neurodegenerative diseases are often associated
with neuroinflammatory processes that may not only
occur in response to neuron loss but may also contribute
to it [15,16,27-30]. Because certain inflammatory
responses in the brain are required for clearing cellular
debris, limiting tissue damage, and contributing to
wound repair, it is critical that inflammatory factors and
mechanisms that contribute to neurotoxicity and compro-
mise neuronal survival be identified and selectively tar-
geted without interfering with the neuroprotective effects
of glial activities [18]. Our previous studies established a
critical role for TNF as a mediator oxidative neurotoxin-
and endotoxin-induced dopaminergic neuron death in
models of PD [26]. The ability of CDDO-Me to inhibit
new synthesis of TNF in microglia and to effectively
reduce soluble TNF production by activated cells offers
one possible mechanism by which the anti-inflammatory
properties of CDDO-Me affords protection to dopaminer-
gic cells.
In addition to its anti-inflammatory properties, CDDO-
Me may be able to boost or strengthen the immune sys-
tem through upregulation of IL-2 signaling. IL-2 has been
shown to be critical for survival, proliferation and differ-
entiation of T-cells into effector cells and to confer a sur-
vival advantage to CD4+ T-cells to facilitate development
of a memory population [37,38]. In chronic inflamma-
tory syndromes characterized by persistent elevation of
pro-inflammatory cytokines, localized IL-2 depletion at
sites of inflammation has been shown to be the most pro-
found effect of long term exposure to TNF [39]; our data
suggests that therapeutic use of CDDO-Me may be able to
reverse this phenomenon.
The observed antioxidant effects of CDDO-Me are not sur-
prising given that synthetic triterpenoids have been
shown to activate Nrf2, the key transcription factor that
globally regulates the phase II detoxification pathway.
Regardless of whether the primary antioxidant effect of
CDDO-Me is mediated via direct action on neuronal pop-
ulations or by suppression of glial-derived extracellular
ROS production to reduce oxidative stress in neurons, the
mechanisms by which synthetic triterpenoids exert anti-
oxidant effects merit further investigation in animal mod-
els of neurodegeneration where oxidative stress is believed
to be the primary mediator of neuron death. In support of
this idea, it was recently reported that feeding pharmaco-
logical inducers of the phase II detoxification pathway to
Drosophila parkin mutants or flies overexpressing α-synu-
clein suppressed the neuronal loss in both models of Par-
kinson's disease [40].
In summary, our findings indicate that in response to spe-
cific inflammatory triggers, CDDO-Me is able to differen-
tially regulate microglial activities without compromising
either microglial survival or the ability of microglia to per-
form basic functions (i.e. phagocytosis). Moreover, the
ability of CDDO-Me to limit production and secretion of
neurotoxic pro-inflammatory cytokines and to attenuate
intracellular ROS accumulation strongly suggest that
chronic administration of brain-permeant synthetic triter-
penoids will confer neuroprotection in vivo. Several other
anti-inflammatory agents have been reported to have neu-
roprotective properties in in vitro and in vivo models of
Parkinson's disease. Specifically, the tetracycline deriva-
tive minocycline, which inhibits TNF synthesis, potently
attenuates DA neuron loss resulting from nigral LPS treat-
ment of rats [41]. Similarly, thalidomide (a non-selective
immune modulating drug that reduces TNF expression
through degradation of TNF mRNA) has been demon-
strated to partially attenuate dopamine depletion in an
MPTP mouse model of PD [42]. Naloxone, an opioid
receptor antagonist, protected rat DA neurons against
inflammatory damage through inhibition of microglia
activation and superoxide generation [43]; and the kappa-
CDDO-Me enhances phagocytic activity of BV2 microglia  induced by TNF or LPS + fibrillar Aβ 1–42 peptide Figure 7
CDDO-Me enhances phagocytic activity of BV2 
microglia induced by TNF or LPS + fibrillar Aβ 1–42 
peptide. BV2 microglia were plated, switched to serum-free 
media 24 hours later, and stimulated overnight as indicated 
(LPS, 10 ng/mL; TNF, 10 ng/mL; fAβ42, 1 μM; and CDDO-
Me, 10 nM.). Fluorescently-labeled E. coli particles were 
added to the cultures for 2 hours following stimulation and 
phagocytosis of particles was measured by fluorescence 
emission at 520 nm. Values represent mean phagocytic activ-
ity relative to baseline (vehicle-stimulated control) ± SEM. 
Values were analyzed by two-way ANOVA followed by 
Tukey's post hoc test, * denotes CDDO-Me is significantly 
different from its DMSO vehicle for a given treatment; # 
denotes significant difference from the DMSO vehicle in 
unstimulated cells; + denotes significant difference from 
CDDO-Me in stimulated cells; all symbols at p < 0.05.Journal of Neuroinflammation 2008, 5:14 http://www.jneuroinflammation.com/content/5/1/14
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opioid receptor agonist dynorphin A (1–17) attenuated
inflammation-mediated degeneration of DA neurons in
rat midbrain neuron-glia cultures [44]. In addition, dex-
tromethorphan (DM), an ingredient widely used in anti-
tussive remedies, has been shown to reduce the
inflammation-mediated degeneration of DA neurons
through inhibition of microglial activation [45]. There-
fore, the neuroprotective properties of CDDO-Me and
related compounds merit further investigation in pre-clin-
ical animal models of PD.
Lastly, it may be of interest to determine the extent to
which the CDDO-Me-induced enhancement of microglial
phagocytic activity observed in our in vitro studies can be
achieved in vivo with brain-permeant synthetic triterpe-
noids. This issue may be of particular therapeutic rele-
vance in the treatment of AD because pro-inflammatory
cytokines, including TNF, have been shown to preferen-
tially attenuate phagocytic activity of microglia induced
by fibrillar Aβ amyloid peptides (but not by IgG antibody
activation of Fc Receptor) through an E prostanoid recep-
tor-dependent mechanism [46]. On the basis of our
results, we speculate that synthetic triterpenoids will be
able to promote fibrillar amyloid clearance by potentiat-
ing the phagocytic activity of microglia at plaque sites
characterized by inflammation where TNF is locally ele-
vated. If synthetic triterpenoids can promote plaque clear-
ance, their use as an adjunct therapy to reduce amyloid
burden in patients with AD may be beneficial.
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